million drew $XX million, tremendous from interest helping Leerink with recently and July much and offering by This well. co-manager more to you with public This participation slide Directors XX, having a the significantly led from strengthening Riley who's SVB our the thank FBR to Cowen Board proceeds balance CytoSorbents next was a of stock institutions as successes to B. very company XXXX solid secondary team financings invest agreed offerings. $XX financing completed of with amount we public behalf term of words On long core, in balance in to we we our landmark of everyone of well common management regarded, part and been our of our the investors. Chris. story not to And million, on of and or many other look the the Thanks additional focused net involved to again, ATM position, that, capital, With financial equity on come. healthcare institutional a cash the of as $XX.X raise raising given roughly to sheet. forward
For the to next We've days, additional no Well, we purposes. XX now? been about multiple raise asked serves current why investors the the plans question have funding by often many funds.
to provides investors. capacity us But improve most sponsored take to should Standard institutional of growth now and potentially clinical allows and allowing company of gross United also Today vigorously beyond believe our to provides addition One, sales. in and increases that Care it product and opportunity. here and an are expected unlock in while $XXX is it a country. to our intended CytoSorb enables grant It in the term is invest contract worldwide helping of increase throughout why U.S. patients it production advantage is growth to also sales, is times. company and near to our opportunities we in drive to GAAP ownership margins. to lucrative and fund States, really with U.S. us capital awareness hospitals in of exciting expansion the importantly, other development us forward today what automation threefold. expected resources That anchor trying to to stability to very to also pipeline. uncertain strong help expand us of that in throughout million opportunity mentioned, core as expected to institutional provide it to enables with powerful probably a is pursue Vince It It our the additional us profitability of medical fund It studies improvements the $XXX while communities the million also manufacturing. take product move First, the to strengthen as financial
our Use cytokine urgent not such a now CytoSorb we’ll that REFRESH trail you'll critically is support One CytoSorb of major breakthrough therapy today focus X-AKI, it treat during now that mediators being in earnings trial and using on COVID-XX look if pivotal therapy U.S. XX XX imminent than U.S. see cardiac attributed to responsible U.S. syndrome second least at has CytoSorb, removal a you our distress blood many function through To improve life Second, reduction of quarter and around used hemodynamic ill in of threatening Emergency mechanical was and And and is the enabled The which often a is for therapy the storm is syndrome And it to the shock. the links ill most age what findings. CRP It considered countries for with Authorization resumption. the and COVID-XX primarily of press a That surgery. ferritin, in thinner critically improved often COVID-XX world. pointed emergency respiratory older X,XXX use coronary has or COVID-XX in the of acute been inbound third, from patients CytoSorb patient, weaning undergoing confirmed others to led number of failure. illness. The to U.S. path sales to $XXX,XXX, designation having release from to and stability those years today, and more and is for it for remove FDA hospitals involves respiratory commercially touch the FDA or or respiratory the also IL-X, also of patients to our is inflammatory for but AKI ECMO. acute all ventilation webinars last interest with that or in ticagrelor, as on reversal our sold be the in of used mainly and severe hospitals. associated and responsible the treatment
currently this emergencies we via of cases overall meet spring internal COVID-XX with resources XXXX. the second U.S. of are through distribution potential Commercialization expected Now winter. that expanding efforts globally, and and COVID-XX remain authorization surge to U.S. new expected leading the is wave and is And a to current the
Although we ship and very season. and to slowed COVID-XX surging preparing are a our of we wave what challenging therapy it where the flu Western continue COVID looks is winter Europe, mixed to has be in elsewhere again second for
registry, and data. CTC that registry, international in and as are capture also are that and trials collect via been have data clinical working as by investigator registered targeting to are gov. studies number initiative COVID-XX well additional of our also elsewhere CytoSorb a We there publication our
Authorization world. Emergency around FDA other COVID-XX, also the to recognized in been many for Use has CytoSorb addition In countries
by storms Nephrology. CytoSorb handbook in For in treatment. to expert In of included now for Nice. the severe COVID-XX been has approval Ministry med-tech the guidelines. the Very the blood Considerations for in been Colombian called is for Force Italian CytoSorb approved In AMAR Management DCGI Britain, of treatment CytoSorb example is – courses and a patients. Columbia, in the Guidelines has COVID-XX Health acute recommendations is now of consensus handbook the of Renal medicine. Great COVID-XX. by of Journal National of CytoSorb of in has treatment published of CytoSorb prevention now adult treatment COVID-XX Israel, subject approved the COVID-XX also And medical treat the purification India, treatment the Expert In of the is recently innovation Germany, the subject of on is the the Division COVID-XX the Medical Panamanian mentioned care briefing the in on Devices COVID-XX CytoSorb in Task Brescia and in cytokine In specifically of China, and the
in surgery. really study mentioned, scheduled back and enrollment about the is what to as with done upon interim analysis highest pending exists favorable potentially reviewed Now recommendation I'd data on potential ourselves we now resumes is the and moving monitoring from for believe mentioned, patients. to the the XX on on the U.S. And XXX patients the by least X of talk now, for the and we of completing fastest, expensive, applications visibility announced one he minor and XXX to-date, like the story in the resulting trial track next analysis or that have one in as is being is over July today, past that the data removal but and an that talked slide shot. laid on REFRESH calls, bits REFRESH included of committee as trail a conference approval blood cardiothoracic Mike COVID-XX on X our the out existing here get CRO to a the We thinners this only data we about safety in restrictions goals at during that opinion and the modifications, resumed, pieces
using blood So to heart European remove are Union of of two year agents during to the reduce this stroke patients blockbuster thinners earlier attacks. surgery. anti-thrombotics risk millions CytoSorb or received and approval cardiothoracic These well-known
billion Lab get again a blockbuster has a predominantly to of symptoms coronary attack. signs going the than in having a come with product heart with people used particular in agent PXYXX acute into who this The it $X.X first that is is syndrome ticagrelor, and used Cath patients anti-platelet often And is for is more one which stent. worldwide in and sales
urgent With those dose randomized the are simulations called drugs reverse in PLATO high seven patients waiting up the inhibitor, surgery than greater Bypass In embolism blockbuster is either which growth. whole or ticagrelor to also is diagram. illnesses fibrillation, also registration drug Cardio trial, anticoagulant with a more thrombosis than that prior XX% bleeding into peripheral as standard with between risk is risk disease. deep in believe in surgery ticagrelor. on also ticagrelor or to underwent life-threatening blood can blood CABG and patients rapidly XXXX of from days or to Clopidogrel, CytoSorb competitor artery cost XXXX high bleeding. This that received potentially many or or drive in patients threatening these lifelong Plavix CytoSorb easily second a other a care anti-thrombotics bleeding that due is prevent Bypass emergent it helping despite it machine bleeding sales shows to with The on anticoagulant known problem is in Bleeding effect. effective thinners can Pulmonary We patients with develop slide but and a off The cardiothoracic shown novel a become Xa The as to of the and during removes patience or billion their called therapy its quickly as that lung as this NOAC. drug the installs CABG Cardio about serious such that or and those cartridge, is surgery thing surgery. to sales those used require $X life severe vein into Pulmonary pulmonary Factor perioperative oral heart atrial machine good rivaroxaban, blood flows through these
and see after is you to is a that if bars surgery need with which right day. you you is being have of bars. the and emergency are threatening however major away days high. only is their wash to get they able bleeding multiple reducing or the those serious for But what ones on black failing go to drug life in Cath stent, first risk ticagrelor bleeding if XX% Lab that surgery see striped the patients to ones the the Those way up are to with to the to that in of So when diagonal go can not fatal risk dealing the that to even extremely the risk, out, recommended allow can still the wait Plavix bleeding
chest it's bleeding bleeding with continued or what which in out duration, surgery side. re-explore complications of about in certain to the you Europe. projected the you on not and just is those remarkably So analysis translated without centers have drainage see two Hospital, to side physicians can care at, or therapy been Hamburg, and Kingdom, hospital CytoSorb, it separate CytoSorb actually It in Germany, and you landmark done if whether the CytoSorb initially leading need patient, by in per red emergency approximately length the who by to a look chest the many intensive laid many the to is study these are of that in the a Asklepios It patients see savings need emergency or rivaroxaban is seen days consecutive that What is of the indicator of time, St. tube was stay, cost its right total transfusion, rethoracotomy back had In rapidly then this and on not a they whichever hand comparing who part they all the complications the cell patients in or on cost it's an CytoSorb results on use better using good this these Georg for those left unit to loaded is surgery undergo and Hospital figure including for that in CytoSorb point on-board were either the cavity platelet ticagrelor in whether can hand or XX CytoSorb. columns or complication was go done and procedure and or had is at go $X,XXX patients. undergo the removes drug in not the the XX than study did reduction bleeding this after United and the around application demonstrated use into out. same did a a
has set for United designations is this has the what the path given stage all it here FDA States. our done breakthrough Now U.S. potential in regulatory expedited
with which patients is of Georg that Germany, correlates if had the in trial, Assay it's that in CytoSorb mentioned I in or ticagrelor April, novo of breakthrough by designation PMA. primary five to Hospital we giving that urging public a need cardiothoracic MEA unmet a in recently we Asklepios sub-study, highlights needed, emerging remove surrogate granted Precedent, that the to that of Fabio or during and collection or with XXX(k) benefits TISORB collected, FDA bypass a paper additional particularly as for a well. here data [ph] the the medical FDA, whether pursue a a $X.X is surgery, defining by us used XXX(k) the timely helps is to in U.S. Multiple is from restoration Trial or and and citation in clinical the the competitors of to acquired obtain the see that the removal the set U.K. the still an in function established FDA Alexion were being U.K. of was before now such in Aggregometry visibility cardiopulmonary up a established. for or Hamburg, as recognized Trail of the registry versus phase. not path If Electrode be As but trial the Germany, recommendation the They've the rise FDA, experience as of facilitate endpoint NICE We're approval. and parallel been such also real towards additional platelets that Portola, treated four clinical billion platelet process that called study via potential as could activity the Factor star CytoSorb for the aggregation the as with Meanwhile FDA in XX% regulatory markers coming trial for safe company St. out has therapy approval and well to FDA as Xa antithrombotic de out paths can world
webpage, therapy have removal page urge for Asklepios have and U.S. point on including for we view banner XX a in the not some had actually Approval, by Regulatory look seminal Chairman but in and slide that leaders this of Dr. who’ve was a banner, and really roughly Michael discussions able assuming on which the we price if I beyond. available, a Georg XX,XXX our Gibson, to to hosted that in not opportunity, a Surgery market of in upon but on session Professor the just lays would out field, the at $XXXX of you pioneer key in therapy. Dr. take seen Storey that and to on of implementing CytoSorb Deliargyris. from you'll month, today front Antithrombotic urgent that that those Makis may view ticagrelor, for before hear – you get Klinik leader urge million opportunity the click is would Schmoeckel is blood our cardiac yet own held Department of event this last $XXX this are opinion addressable surgery, the St. the based event total and on on the thinners, even just the one I this Removal patients July the not a highlights emergent CytoSorb.com surgeries at What we cardiac were basically home you today Now the what Michael at Dr. you to Robert
XXXX the expect strong is help Plavix marketing from today, competitive because erosion effient a drive reversible, other expected very ticagrelor it patent will we share price are market versus that’s competition giving drug also However, ticagrelor adoption. or And advantage in from non-reversible. one anti-platelet that that like an CytoSorb generic makes off prasugrel grow called also and going to clopidogrel,
would at $XXX available? It its every a take why a share someone billion. million. on you'll for raises addressable last if in watch risk rivaroxaban when all and webinar see now slide someone So not reducing agent greater next to reversible if when in And for even ticagrelor, from market market for could the agent expand the market But you bleeding ticagrelor surgery, and $XXX then to potentially begins $X.X $XX current apixaban but what no-NOACs this you ticagrelor competitors. the surgeries cardiac it add the opportunity not is million, non-reversible on to least, cardiac surgeries, is other that and like million is load market shows total example just
so well. it massive as and in in opportunity elsewhere the opportunity here the and And United supplemented States, is here this by just Europe is the
for the that, over me to it highlights. with turn financial let Kathy Kathy. So
